# Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity

> **NCT00886535** · — · COMPLETED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 41 (actual)

## Conditions studied

- Breast Cancer
- Ductal Carcinoma in Situ

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00886535
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-12
- **Final completion:** 2017-07-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886535, "Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00886535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*